Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Ixazomib-Rituximab in Untreated Indolent B-NHL: An Effective, Very Low Toxicity Regimen

Solomon A. Graf, MD, Ryan C. Lynch, MD, Ted A Gooley, PhD, Chaitra S. Ujjani, MD, Peter Wilcox, Sabrina Wilcox, David G. Coffey, MD, Andrew J. Cowan, MD, Stephen D. Smith, MD, Mazyar Shadman, MDMPH, Edus H. Warren, MD PhD, Edward Libby, MD, Colin D. Godwin, MDMPhil, Ryan D. Cassaday, MD, Jonathan R. Fromm, MD PhD, Ajay K. Gopal, MD

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-137226

Published: 2020

Journal Articles

High Throughput Drug Synergy Testing in a Clinical Trial of Panobinostat, Carfilzomib, Dexamethasone to Define Response Biomarkers for Relapsed/Refractory Multiple Myeloma

Pamela S. Becker, MD PhD, Kim Quach, Ted A Gooley, PhD, Edward N. Libby, III, MD, Andrew J. Cowan, MD, David G. Coffey, MD, Bret Gary Degraaff, BS, Cody Hammer, Jin Dai, PhD, Sylvia Chien, Josh Epworth, ARNP, Gabrielle A Zecha, PA-C, Heather Smith, PA-C, Timothy S Martins, PhD

Blood (2019) 134 (Supplement_1): 1902.

https://doi.org/10.1182/blood-2019-130990

Published: 2019

Journal Articles

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Andrew J. Cowan, MD, Margot Pont, PhD, Blythe Duke Sather, PhD, Cameron J. Turtle, MBBS, PhD, Brian G. Till, MD, Anne M Nagengast, RN, Edward N. Libby, III, MD, Pamela S. Becker, MD PhD, David G. Coffey, MD, Sherilyn A. Tuazon, MD, Brent L Wood, MD PhD, Michelle L Blake, PhD, Melissa G Works, PhD, Ted A Gooley, PhD, Qian Vicky Wu, PhD, David G. Maloney, MD PhD, Stanley R. Riddell, MD, Damian J. Green, MD

Blood (2019) 134 (Supplement_1): 204.

https://doi.org/10.1182/blood-2019-129405

Published: 2019

Journal Articles

A Window Study of Ixazomib in Untreated B-NHL

Solomon A. Graf, MD, Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, David G. Coffey, MD, Andrew J. Cowan, MD, Stephen D. Smith, MD, Mazyar Shadman, MD, Edus H. Warren, MD PhD, Edward N. Libby, III, MD, Colin D. Godwin, MDMPhil, Ryan D. Cassaday, MD, Ted A Gooley, PhD, Jonathan R. Fromm, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5260.

https://doi.org/10.1182/blood-2019-126153

Published: 2019

Journal Articles

High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma

David G. Coffey, MD, Andrew J. Cowan, MD, Timothy S Martins, PhD, Damian J. Green, MD, Edward N. Libby, III, MD, Rebecca W. Silbermann, MD, Sylvia Chien, Jin Dai, PhD, Alicia Morales, Niall Curley, Bret Gary Degraaff, BS, Ted A Gooley, PhD, Edus H. Warren, MD PhD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 1885.

https://doi.org/10.1182/blood-2019-125383

Published: 2019

Journal Articles

Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase

Damian J. Green, MD, Margot Pont, PhD, Andrew J. Cowan, MD, Gabriel O Cole, Blythe Duke Sather, PhD, Anne M Nagengast, RN, Xaoling Song, Sushma Thomas, Brent L Wood, MD PhD, Michelle L Blake, PhD, Melissa G Works, PhD, Ted A Gooley, PhD, David G. Maloney, MD PhD, Stanley R. Riddell, MD

Blood (2019) 134 (Supplement_1): 1856.

https://doi.org/10.1182/blood-2019-129582

Published: 2019

Journal Articles

NaïVe T Cell Depletion of PBSC Grafts Results in Very Low Rates of Chronic Gvhd and High Survival

Marie Bleakley, MDPhD, Ted A. Gooley, PhD, Barbara Hilzinger, RN, Stanley R Riddell, MD, Warren D Shlomchik, MD

Blood (2016) 128 (22): 668.

https://doi.org/10.1182/blood.V128.22.668.668

Published: 2016

Journal Articles

It Is Easix to Predict Non-Relapse Mortality (NRM) of Allogeneic Stem Cell Transplantation (alloSCT)

Thomas Luft, MD PhD, Axel Benner, Sonata Jodele, MD, Christopher E. Dandoy, MD, Rainer F. Storb, MD, Ted A. Gooley, PhD, Brenda M. Sandmaier, MD, Aleksandar Radujkovic, MD, Anthony D. Ho, MD, Peter Dreger, MD, Olaf Penack, MD

Blood (2016) 128 (22): 519.

https://doi.org/10.1182/blood.V128.22.519.519

Published: 2016

Journal Articles

Results of a Phase I-II Study of Fenretinide and Rituximab for Patients with B-Cell Lymphomas

Andrew J. Cowan, MD, Philip Stevenson, M.S., Ted A. Gooley, PhD, Shani L. Frayo, George R. Oliveira, MD, Stephen D. Smith, MD, Damian J. Green, MD, Jennifer E. Roden, John M. Pagel, MD PhD, Brent L Wood, MD PhD, Oliver W Press, MD PhD, Ajay K. Gopal, MD

Blood (2015) 126 (23): 2728.

https://doi.org/10.1182/blood.V126.23.2728.2728

Published: 2015

Journal Articles

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Reduces the Risk of Bacteremia after Myeloablative Cord Blood Transplant

Corinne Summers, MD, Filippo Milano, MD PhD, Ted A. Gooley, PhD, Ann Dahlberg, MD, Colleen Delaney, MD MSC

Blood (2014) 124 (21): 3860.

https://doi.org/10.1182/blood.V124.21.3860.3860

Published: 2014

Journal Articles

Minimal Residual Disease Does Not Impact Risk of Relapse in Myeloablative Umbilical Cord Blood Transplant Recipients: Comparison with Matched and Mismatched Unrelated Transplants

Filippo Milano, MD PhD, Ted A. Gooley, PhD, Brent L. Wood, MD PhD, Ann E Woolfrey, MD, Effie W. Petersdorf, MD, Frederick R. Appelbaum, MD, Colleen Delaney, MD MSC

Blood (2014) 124 (21): 2579.

https://doi.org/10.1182/blood.V124.21.2579.2579

Published: 2014

Journal Articles

Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium

Andrei R. Shustov, MD, Wyndham H Wilson, MD, PhD, Anne W Beaven, MD, Kerry J. Savage, MD, MSc, Kenneth R. Carson, MD, Francisco J. Hernandez-Ilizaliturri, MD, Sindhu Cherian, MD, Ted A. Gooley, PhD, Julie M Vose, MD, MBA

Blood (2013) 122 (21): 3032.

https://doi.org/10.1182/blood.V122.21.3032.3032

Published: 2013

Journal Articles

Donor KIR3DL1 and HLA-B Allotypes Control Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Fabio Giglio, MD, Ted A. Gooley, PhD, Jeffrey M Venstrom, MD, Meighan M Gallagher, LiHua Hou, PhD, Carolyn K Hurley, PhD, Tatiana Lebedeva, MD, PhD, Harriet Noreen, CHS, Raja Rajalingam, PhD, Elaine F Reed, PhD, Neng Yu, MD, Cynthia Vierra-Green, MS, Michael D Haagenson, MS, Mari Malkki, PhD, Effie W. Petersdorf, MD, Stephen Spellman, MBS, Katharine C. Hsu, MD, PhD

Blood (2012) 120 (21): 349.

https://doi.org/10.1182/blood.V120.21.349.349

Published: 2012

Journal Articles

A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Raya Mawad, MD, Ted A. Gooley, PhD, Joseph G Rajendran, MD, Darrell R. Fisher, PhD, Ajay K. Gopal, MD, H. Joachim Deeg, MD, Andrew Shields, MD, Damian J. Green, MD, David G. Maloney, MD, PhD, Brenda M. Sandmaier, MD, Rainer Storb, MD, Frederick R. Appelbaum, MD, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD

Blood (2012) 120 (21): 1924.

https://doi.org/10.1182/blood.V120.21.1924.1924

Published: 2012

Journal Articles

Randomized Comparison of Melphalan 200 Mg/m 2 v. 280 Mg/m 2 As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

William I. Bensinger, MD, Pamela S Becker, MD, PhD, Ted A. Gooley, PhD, Thomas Chauncey, MD, PhD, David G. Maloney, MD, PhD, Robert Vescio, MD, Ajay K. Gopal, MD, Damian J. Green, MD, Oliver W. Press, MD, PhD, Michael Lill, M.D., Leona Holmberg, MD, PhD, Jainulabdeen J Ifthikharuddin, MD, Gordon L. Phillips, II, MD

Blood (2012) 120 (21): 2009.

https://doi.org/10.1182/blood.V120.21.2009.2009

Published: 2012

Journal Articles

A Phase II Trial of Myeloablative I-131-Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Transplantation for B-Cell Non-Hodgkin's Lymphoma

Ajay K. Gopal, MD, Ted A. Gooley, PhD, Joseph Rajendran, MD, John M. Pagel, MD, PhD, Darrell R. Fisher, PhD, David G. Maloney, MD, PhD, Frederick R. Appelbaum, MD, Andrew Shields, MD, Damian J. Green, MD, Oliver W. Press, MD, PhD

Blood (2012) 120 (21): 811.

https://doi.org/10.1182/blood.V120.21.811.811

Published: 2012

Journal Articles

Quantitative Significance of Minimal Residual Disease Before Myeloablative Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First and Second Complete Remission

Roland B. Walter, MD, PhD, Sarah A. Buckley, MD, John M. Pagel, MD, PhD, Brent L. Wood, MD, PhD, Ted A. Gooley, PhD, Brenda M. Sandmaier, MD, Min Fang, MD, PhD, Elihu H. Estey, MD, Jerald P. Radich, MD, Gary Schoch, PhD, Frederick R. Appelbaum, MD

Blood (2012) 120 (21): 655.

https://doi.org/10.1182/blood.V120.21.655.655

Published: 2012

Journal Articles

Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT

Raya Mawad, MD, Paul O'Donnell, MD, PhD, Ted A. Gooley, PhD, Joseph G Rajendran, MD, Darrell R. Fisher, PhD, Ajay K. Gopal, MD, H. Joachim Deeg, MD, Andrew Shields, MD, Damian J. Green, MD, David G. Maloney, MD, PhD, Brenda M. Sandmaier, MD, Rainer Storb, MD, Frederick R. Appelbaum, MD, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD

Blood (2012) 120 (21): 4164.

https://doi.org/10.1182/blood.V120.21.4164.4164

Published: 2012

Journal Articles

A 4-Drug, Weekly Combination Regimen of Bortezomib, Cyclophosphamide, Liposomal Doxorubicin, and Dexamethasone for Initial Treatment of Multiple Myeloma

Pamela S. Becker, MD, PhD, Ted A. Gooley, PhD, Kathy Lilleby, RN, Damian J. Green, MD, Nicholas Burwick, MD, Christine Wallace, Theodore Kim, DO, Kiarash Kojouri, MD, MPH, Erin Nelli, DO, William I. Bensinger, MD

Blood (2012) 120 (21): 5038.

https://doi.org/10.1182/blood.V120.21.5038.5038

Published: 2012

Journal Articles

Impact of Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry Pre and Post Transplantation, On Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

Merav Bar, MD, Brent L. Wood, MD, PhD, Jerald P. Radich, MD, Kristine C. Doney, MD, Frederick R. Appelbaum, MD, Ted A. Gooley, PhD

Blood (2012) 120 (21): 592.

https://doi.org/10.1182/blood.V120.21.592.592

Published: 2012

NARROW

Ixazomib-Rituximab in Untreated Indolent B-NHL: An Effective, Very Low Toxicity Regimen

High Throughput Drug Synergy Testing in a Clinical Trial of Panobinostat, Carfilzomib, Dexamethasone to Define Response Biomarkers for Relapsed/Refractory Multiple Myeloma

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

A Window Study of Ixazomib in Untreated B-NHL

High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma

Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase

NaïVe T Cell Depletion of PBSC Grafts Results in Very Low Rates of Chronic Gvhd and High Survival

It Is Easix to Predict Non-Relapse Mortality (NRM) of Allogeneic Stem Cell Transplantation (alloSCT)

Results of a Phase I-II Study of Fenretinide and Rituximab for Patients with B-Cell Lymphomas

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Reduces the Risk of Bacteremia after Myeloablative Cord Blood Transplant

Minimal Residual Disease Does Not Impact Risk of Relapse in Myeloablative Umbilical Cord Blood Transplant Recipients: Comparison with Matched and Mismatched Unrelated Transplants

Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium

Donor KIR3DL1 and HLA-B Allotypes Control Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Randomized Comparison of Melphalan 200 Mg/m 2 v. 280 Mg/m 2 As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

A Phase II Trial of Myeloablative I-131-Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Transplantation for B-Cell Non-Hodgkin's Lymphoma

Quantitative Significance of Minimal Residual Disease Before Myeloablative Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First and Second Complete Remission

A 4-Drug, Weekly Combination Regimen of Bortezomib, Cyclophosphamide, Liposomal Doxorubicin, and Dexamethasone for Initial Treatment of Multiple Myeloma

Impact of Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry Pre and Post Transplantation, On Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only